Tyra Biosciences (TYRA) Change in Accured Expenses (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Change in Accured Expenses data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 427.4% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 14.97% YoY) and the FY2025 annual result came in at $3.4 million, up 552.82% from the prior year.
• Change in Accured Expenses retreated to $1.2 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.1 million in Q4 2023 to a low of -$6.9 million in Q1 2024.
• A 5-year average of $914470.6 and a median of $1.6 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 9572.92% — and 2024, when it plunged 241.54%.
• Tracing TYRA's Change in Accured Expenses over 5 years: stood at $207000.0 in 2022, then soared by 2352.17% to $5.1 million in 2023, then slumped by 56.5% to $2.2 million in 2024, then declined by 2.36% to $2.2 million in 2025, then plunged by 44.57% to $1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.2 million (Q1 2026), $2.2 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.